RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial tests new arsenal against stubborn blood cancer
Disease control OngoingThis early-stage study is testing the safety and best dose of a three-drug combination for patients with slow-growing non-Hodgkin's lymphoma that has returned or not responded to prior treatment. The drugs work together to help the immune system attack cancer cells and block a pr…
Matched conditions: RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug combo tested to fight tough blood cancers
Disease control OngoingThis study is testing if adding a new drug called selinexor to the standard chemotherapy regimen (RCHOP) is safe and more effective for treating B-cell non-Hodgkin's lymphoma. It will first find the safest dose of the combination, then see how well it works for newly diagnosed pa…
Matched conditions: RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC